Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-
nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human …

Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast
growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However …

Abstract Purpose: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC)
do not harbor mutations in KRAS. Understanding the unique molecular and clinical features …

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many
biological processes. Deregulated FGFR signaling plays an important role in tumor …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Increasing evidence indicates that success of targeted therapies in the treatment of cancer is
context-dependent and is influenced by a complex crosstalk between signaling pathways …

Objectives There is an expanding list of therapeutically relevant biomarkers for non-small
cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition …

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …